Advancing the development of therapeutics against infectious diseases with optimized protein expression systems
Novel and emerging infectious diseases can be a serious threat to human health and the global economy. To mitigate these threats, it is necessary to initiate comprehensive containment strategies such as virus characterization, serological testing, therapeutic antibody research, and vaccine development.
The global crisis caused by the SARS-CoV-2 virus amplified the need to accelerate diagnostics, therapeutics, and vaccine development, spurring new and efficient workflows to combat rapidly evolving pathogens. In recent years, these workflows have harnessed the benefits of protein expression systems for efficient infectious disease research.
This White Paper details:
- How transient protein expression can be employed to further infectious disease research
- How protein expression systems assist in the development of serological assays
- How transient expression workflows can be used to produce therapeutic antibodies
- How these workflows can assist in more efficient identification of lead vaccine candidates
Read the full article, ‘Advancing the development of therapeutics against infectious diseases with optimized protein expression systems’, in the PDF linked below.